Benzylacyclouridine

Benzylacyclouridine (BAU) is a potent and specific inhibitor of uridine phosphorylase, the first enzyme in the catabolism of uridine. Benzylacyclouridine inhibits the metabolic activity of UPP1 and the activity of UPP2. Benzylacyclouridine can modulate the cytotoxic side effects of 5-fluorouracil (5-FU) and its derivatives[1][2][3][4][5].

Product Specifications

CAS Number

[82857-69-0]

Product Name Alternative

BAU; 5-Benzylacyclouridine

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Drug Derivative

Type

Reference compound

Related Pathways

Others

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/benzylacyclouridine.html

Concentration

10mM

Purity

98.18

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

OCCOCN(C(NC1=O)=O)C=C1CC2=CC=CC=C2

Molecular Formula

C14H16N2O4

Molecular Weight

276.29

Precautions

H302, H315, H319, H335

References & Citations

[1]Pizzorno G, et, al. Phase I clinical and pharmacological studies of benzylacyclouridine, a uridine phosphorylase inhibitor. Clin Cancer Res. 1998 May;4 (5) :1165-75.|[2]Roosild TP, et, al. Implications of the structure of human uridine phosphorylase 1 on the development of novel inhibitors for improving the therapeutic window of fluoropyrimidine chemotherapy. BMC Struct Biol. 2009 Mar 16;9:14.|[3]Monks A, et, al. Effect of 5-benzylacyclouridine, a potent inhibitor of uridine phosphorylase, on the metabolism of circulating uridine by the isolated rat liver. Biochem Pharmacol. 1983 Jul 1;32 (13) :2003-9.|[4]Whyte D, et al. Uridine phosphorylase-1 supports metastasis by altering immune and extracellular matrix landscapes. EMBO Rep. 2025 Jul 23. |[5]Sohn JH, et al. Liver mitochondrial cristae organizing protein MIC19 promotes energy expenditure and pedestrian locomotion by altering nucleotide metabolism. Cell Metab. 2023 Aug 8;35 (8) :1356-1372.e5.